US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Pin-Away PYRENTAL PAMOATE

Reason CGMP Deviations: Use of non-food grade lubricant in mixing vessel.

Denison Pharmaceuticals, LLC NDC 70309-080-02 D-0774-2023
Class II · Moderate risk Ongoing

Colic Calm

Reason CGMP Deviations: Use of non-food grade lubricant in mixing vessel.

Denison Pharmaceuticals, LLC D-0773-2023
Class II · Moderate risk Ongoing

Safe tussin DM

Reason CGMP Deviations: Use of non-food grade lubricant in mixing vessel.

Denison Pharmaceuticals, LLC D-0772-2023
Class II · Moderate risk Ongoing

FentaNYL 500 mcg

Reason Lack of Assurance of Sterility

Apollo Care, LLC NDC 71170-950-25 D-0646-2023
Class II · Moderate risk Ongoing

Ketamine Injection

Reason Lack of Assurance of Sterility

Apollo Care, LLC NDC 71170-050-05 D-0635-2023
Class II · Moderate risk Ongoing

FentaNYL 50 mcg/mL

Reason Lack of Assurance of Sterility

Apollo Care, LLC NDC 71170-910-25 D-0634-2023
Class II · Moderate risk Ongoing

Succinylcholine Cl Injection

Reason Lack of Assurance of Sterility

Apollo Care, LLC NDC 71170-020-05 D-0633-2023
Class II · Moderate risk Ongoing

PHENYLephrine HCl Injection

Reason Lack of Assurance of Sterility

Apollo Care, LLC D-0632-2023
Class II · Moderate risk Ongoing

Pyrazinamide

Reason CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

RemedyRepack Inc. NDC 70518-2534-01 D-0578-2023
Class II · Moderate risk Ongoing

Ketotifen Fumarate 0.025 %

Reason CGMP Deviations: Discontinuation of the Quality program by manufacturer that would assure product meet the identity, strength, quality, and purity characteristics that they are purported or represented to possess.

RemedyRepack Inc. NDC 70518-1142-00 D-0577-2023
Class II · Moderate risk Ongoing

Tropicamide Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0864-2023
Class II · Moderate risk Ongoing

Ropivacaine Hydrochloride Injection USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0863-2023